BioCentury
ARTICLE | Company News

BMS out-licenses programs to Biogen, Roche

April 13, 2017 7:32 PM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) said Thursday it out-licensed a pair of programs to Biogen Inc. (NASDAQ:BIIB) and Roche (SIX:ROG; OTCQX:RHHBY). Spokesperson Chrissy Trank told BioCentury the deals end BMS's clinical development of therapies for genetically defined diseases.

Biogen received rights to BMS-986168, a mAb targeting microtubule-associated protein tau (tau; MAPT; FTDP-17) which has completed a Phase Ib trial to treat progressive supranuclear palsy (PSP). Biogen said it intends to start Phase II trials “rapidly” in PSP and Alzheimer's disease...